8-hydroxyquinoline sulfate | CAS:134-31-6

We serve 8-hydroxyquinoline sulfate CAS:134-31-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
8-hydroxyquinoline sulfate

Chemical Name:8-hydroxyquinoline sulfate
CAS.NO:134-31-6
Synonyms:Quinolin-8-ol sulfate; 8-Quinolinone Sulfate Monohydrate; Chinosol Monohydrate; 8-hydroxyquinoline sulphate;
Molecular Formula:C18H16N2O6S
Molecular Weight:388.39400
 
Physical and Chemical Properties:
Density:1.26;
Melting point:175oC;
Boiling point:267oC;
Flash point:143.1oC;
 
Specification:
Appearance:Yellow crystalline powder
Purity(HPLC):≥99.0%
Residue on ignition:≤0.2%
Loss on drying:≤0.2%
Fe content:≤100ppm
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Hair dyes intermediate
 



Contact us for information like 8-hydroxyquinoline sulfate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,8-hydroxyquinoline sulphate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,8-hydroxyquinoline sulfate Use and application,8-hydroxyquinoline sulfate technical grade,usp/ep/jp grade.


Related News: Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors.4-AMINO-5-CHLORO-1,2,3-BENZOTHIADIAZOLE manufacturer It also said it would bar South Koreans from visiting China as tourists.2-METHYL-5-HYDROXY PYRIDINE supplier It also said it would bar South Koreans from visiting China as tourists.4-Methylbenzotrifluoride vendor In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.